• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定制吸入疗法以满足 COPD 患者的需求。

Customizing inhaled therapy to meet the needs of COPD patients.

机构信息

Department of Family Medicine, UCLA School of Medicine, Los Angeles, CA 90077, USA.

出版信息

Postgrad Med. 2010 Mar;122(2):83-93. doi: 10.3810/pgm.2010.03.2125.

DOI:10.3810/pgm.2010.03.2125
PMID:20203459
Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by airflow limitation resulting from emphysema and chronic bronchitis. Inhaled therapy is the major therapeutic approach for treating COPD. Multiple inhaler medications are available in the United States and are delivered by a variety of different devices: metered-dose inhalers, dry powdered inhalers, and nebulizers. Each inhaler device has unique requirements for use that must be correctly performed by the patient for successful drug delivery. Patients with COPD represent a medically diverse population, with each patient having distinct characteristics, such as lung function, comorbidities, cognitive functions, hand strength, and lifestyle. These characteristics impact the patient's ability to properly use specific inhaler devices and therefore affect adherence to therapy, therapeutic outcomes, and quality of life. It is estimated that between 28% to 68% of patients do not use metered-dose inhalers or dry powder inhalers correctly. Worsening symptoms or increased frequency of exacerbations may not always indicate disease progression but may indicate a patient's inability to use their inhaler device properly. This review discusses the patient- and device-specific factors to be considered when choosing an inhaled therapy, which will be concordant with the patient's medical needs, preferences, and lifestyle. The review also considers how the ideas underlying the patient-centered medical home model can be incorporated into the choice and use of inhaler device for a given patient with COPD to improve treatment outcomes.

摘要

慢性阻塞性肺疾病(COPD)是一种渐进性疾病,其特征是气流受限,由肺气肿和慢性支气管炎引起。吸入疗法是治疗 COPD 的主要治疗方法。在美国有多种吸入器药物可供选择,并通过各种不同的设备进行输送:计量吸入器、干粉吸入器和雾化器。每种吸入器设备都有其独特的使用要求,患者必须正确操作才能成功输送药物。COPD 患者代表了一个医学多样化的人群,每个患者都有独特的特征,如肺功能、合并症、认知功能、手部力量和生活方式。这些特征会影响患者正确使用特定吸入器设备的能力,从而影响治疗依从性、治疗效果和生活质量。据估计,有 28%至 68%的患者没有正确使用计量吸入器或干粉吸入器。症状恶化或加重的频率增加并不总是表明疾病进展,而可能表明患者无法正确使用他们的吸入器设备。本文综述讨论了在选择吸入治疗时需要考虑的患者和设备特定因素,这将与患者的医疗需求、偏好和生活方式相一致。本文还考虑了如何将以患者为中心的医疗之家模式的基本理念纳入 COPD 患者吸入器设备的选择和使用中,以改善治疗效果。

相似文献

1
Customizing inhaled therapy to meet the needs of COPD patients.定制吸入疗法以满足 COPD 患者的需求。
Postgrad Med. 2010 Mar;122(2):83-93. doi: 10.3810/pgm.2010.03.2125.
2
Inhalatory therapy training: a priority challenge for the physician.吸入疗法培训:医师面临的一项首要挑战。
Acta Biomed. 2007 Dec;78(3):233-45.
3
Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.比较雾化器、定量吸入器和干粉吸入器的临床特征。
Respir Care. 2005 Oct;50(10):1313-21; discussion 1321-2.
4
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.对于患有稳定的中重度慢性阻塞性肺疾病(COPD)的成年受试者,使用压力定量吸入器(pMDI)和储雾罐给药的噻托溴铵产生的支气管扩张反应与使用旋转式吸入器给药的相似。
Respir Med. 2007 Dec;101(12):2464-71. doi: 10.1016/j.rmed.2007.07.006. Epub 2007 Aug 24.
5
Inhaler devices for patients with COPD.慢性阻塞性肺疾病患者的吸入器设备。
COPD. 2013 Aug;10(4):523-35. doi: 10.3109/15412555.2012.761960. Epub 2013 Mar 28.
6
Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.长期管理稳定期哮喘和慢性阻塞性肺疾病时吸入性糖皮质激素给药装置选择的指导因素:聚焦于布地奈德
Respir Med. 2005 Jul;99(7):836-49. doi: 10.1016/j.rmed.2005.02.012. Epub 2005 Mar 23.
7
[Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].[Respimat®,首款软雾™吸入器:慢性阻塞性肺疾病管理的新视角]
Rev Mal Respir. 2010 Dec;27(10):1141-9. doi: 10.1016/j.rmr.2010.10.024. Epub 2010 Nov 18.
8
Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy.慢性阻塞性肺疾病(COPD)治疗方法比较:雾化器、定量吸入器及联合治疗
Am J Med. 2007 May;120(5):435-41. doi: 10.1016/j.amjmed.2006.07.043.
9
The role of nebulized therapy in the management of COPD: evidence and recommendations.雾化治疗在 COPD 管理中的作用:证据与建议。
COPD. 2012 Feb;9(1):58-72. doi: 10.3109/15412555.2011.630047.
10
The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.吸入装置的重要性:吸入装置的选择可能导致慢性阻塞性肺疾病(COPD)患者的依从性欠佳。
Int J Chron Obstruct Pulmon Dis. 2015 Oct 29;10:2335-45. doi: 10.2147/COPD.S90155. eCollection 2015.

引用本文的文献

1
Perceptions and Attitudes of Patients and Their Family Caregivers on Nebulization Therapy for COPD.慢性阻塞性肺疾病患者及其家庭照护者对雾化治疗的认知和态度。
Int J Chron Obstruct Pulmon Dis. 2022 Sep 14;17:2277-2288. doi: 10.2147/COPD.S367819. eCollection 2022.
2
Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers.低载药量阻碍了含肽药物的定量吸入器的临床转化。
Pharmaceuticals (Basel). 2022 Mar 23;15(4):389. doi: 10.3390/ph15040389.
3
Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home.
在 COVID-19 时代及以后用吸入药物治疗 COPD 患者:居家患者的选择和理由。
Int J Chron Obstruct Pulmon Dis. 2021 Sep 28;16:2687-2695. doi: 10.2147/COPD.S332021. eCollection 2021.
4
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.慢性阻塞性肺疾病治疗中的患者考量:聚焦新型吸入剂糠酸氟替卡松/乌美溴铵/维兰特罗
Patient Prefer Adherence. 2018 Jun 8;12:993-1001. doi: 10.2147/PPA.S152179. eCollection 2018.
5
Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair versus HandiHaler in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial.对于慢性阻塞性肺疾病成人患者,通过Diskair与HandiHaler每日一次吸入18μg噻托溴铵的支气管扩张疗效:随机、活性药物对照、平行组、开放标签的IV期试验。
Int J Chron Obstruct Pulmon Dis. 2016 Nov 22;11:2859-2867. doi: 10.2147/COPD.S119114. eCollection 2016.
6
Inhaler assessment in COPD patients: A primer for pharmacists.慢性阻塞性肺疾病患者的吸入器评估:药剂师入门指南。
Can Pharm J (Ott). 2016 Sep;149(5):268-273. doi: 10.1177/1715163516660573. Epub 2016 Jul 27.
7
Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.慢性阻塞性肺疾病(COPD)患者对两种干粉吸入器的正确使用、易用性及偏好:五项III期随机试验分析
Int J Chron Obstruct Pulmon Dis. 2016 Aug 16;11:1873-80. doi: 10.2147/COPD.S109121. eCollection 2016.
8
Assessment of inhaler techniques employed by patients with respiratory diseases in southern Brazil: a population-based study.巴西南部呼吸系统疾病患者吸入器技术使用情况评估:一项基于人群的研究。
J Bras Pneumol. 2014 Oct;40(5):513-20. doi: 10.1590/s1806-37132014000500007.
9
Inhaler use in adolescents and adults with self-reported physician-diagnosed asthma, bronchitis, or emphysema in the city of Pelotas, Brazil.在巴西皮洛塔斯市,有自我报告的医生诊断为哮喘、支气管炎或肺气肿的青少年和成年人使用吸入器的情况。
J Bras Pneumol. 2013 May-Jun;39(3):287-95. doi: 10.1590/S1806-37132013000300005.
10
Examining markers of safety in homecare using the international classification for patient safety.使用国际患者安全分类检查家庭护理中的安全标志物。
BMC Health Serv Res. 2013 May 24;13:191. doi: 10.1186/1472-6963-13-191.